Positive efficacy data prompts Novo Nordisk to stop a kidney outcomes trial (FLOW) that was studying the effects of Ozempic (semaglutide) versus place...
Care Access says an FDA inspection cleared it of good clinical practice violations that had been alleged by Pfizer during its VALOR Lyme disease vacci...
Federal Register notice: FDA determines that certain formulations of Baxter Pharmaceuticals Cytoxan (cyclophosphamide) for injection were not withdraw...
FDA clears a DePuy Synthes 510(k) for the TriLEAP Lower Extremity Anatomic Plating System, a modular, procedure-specific device for use in orthopedic ...
FDA warns Danvers, MA-based Abiomed about Quality System, Medical Device Reporting, and other violations in its marketing of Impella pumps and their C...
FDA issues Warning Letters to two online marketers promoting unapproved glucagon-like peptide-1 receptor agonists semaglutide and tirzepatide.
Three stakeholder organizations suggest changes to an FDA draft guidance on postmarketing approaches to obtain data on populations underrepresented in...
FDA releases the form FDA-483 with 14 observations from an inspection at the New Brunswick, NJ-based Spectrum Laboratory Products repacking/relabeling...
